Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Dynamic changes in HLA-DR expression during short-term and long-term ibrutinib treatment in patients with chronic lymphocytic leukemia

G. Manukyan, P. Turcsanyi, Z. Mikulkova, G. Gabcova, R. Urbanova, P. Gajdos, V. Smotkova Kraiczova, S. Zehnalova, T. Papajik, E. Kriegova,

. 2018 ; 72 (-) : 113-119. [pub] 20180810

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc19028250

Grantová podpora
NV16-32339A MZ0 CEP - Centrální evidence projektů

There is the first evidence of changes in the kinetics of B cell antigen receptor (BCR) internalisation of neoplastic cells in chronic lymphocytic leukemia (CLL) after the short-term and long-term administration of ibrutinib. We aimed to assess the influence of short-term and long-term ibrutinib treatment on the HLA-DR expression on CLL cells, T cells and monocytes. The immunophenotyping of CLL and immune cells in peripheral blood was performed on 16 high-risk CLL patients treated with ibrutinib. After early ibrutinib administration, the HLA-DR expression on CLL cells reduced (P = 0.032), accompanied by an increase in CLL cell counts in peripheral blood (P = 0.001). In vitro culturing of CLL cells with ibrutinib also revealed the reduction in the HLA-DR expression at protein and mRNA levels (P < 0.01). The decrease in HLA-DR on CLL cells after the first month was followed by the gradual increase of its expression by the 12th month (P = 0.001). A one-month follow-up resulted in elevated absolute counts of CD4+ (P = 0.002) and CD8+ (P < 0.001) T cells as well as CD4+ and CD8+ cells bearing HLA-DR (P < 0.01). The long-term administration of ibrutinib was associated with the increased numbers of CD4+ bearing HLA-DR (P = 0.006) and elevation of HLA-DR expression on all monocyte subsets (P ≤ 0.004). Our results provide the first evidence of the time-dependent immunomodulatory effect of ibrutinib on CLL and T cells and monocytes. The clinical consequences of time-dependent changes in HLA-DR expression in ibrutinib treated patients deserve further investigation.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19028250
003      
CZ-PrNML
005      
20190819115108.0
007      
ta
008      
190813s2018 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.leukres.2018.08.006 $2 doi
035    __
$a (PubMed)30149317
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Manukyan, Gayane $u Department of Immunology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic; Laboratory of Molecular and Cellular Immunology, Institute of Molecular Biology NAS RA, Yerevan, Armenia.
245    10
$a Dynamic changes in HLA-DR expression during short-term and long-term ibrutinib treatment in patients with chronic lymphocytic leukemia / $c G. Manukyan, P. Turcsanyi, Z. Mikulkova, G. Gabcova, R. Urbanova, P. Gajdos, V. Smotkova Kraiczova, S. Zehnalova, T. Papajik, E. Kriegova,
520    9_
$a There is the first evidence of changes in the kinetics of B cell antigen receptor (BCR) internalisation of neoplastic cells in chronic lymphocytic leukemia (CLL) after the short-term and long-term administration of ibrutinib. We aimed to assess the influence of short-term and long-term ibrutinib treatment on the HLA-DR expression on CLL cells, T cells and monocytes. The immunophenotyping of CLL and immune cells in peripheral blood was performed on 16 high-risk CLL patients treated with ibrutinib. After early ibrutinib administration, the HLA-DR expression on CLL cells reduced (P = 0.032), accompanied by an increase in CLL cell counts in peripheral blood (P = 0.001). In vitro culturing of CLL cells with ibrutinib also revealed the reduction in the HLA-DR expression at protein and mRNA levels (P < 0.01). The decrease in HLA-DR on CLL cells after the first month was followed by the gradual increase of its expression by the 12th month (P = 0.001). A one-month follow-up resulted in elevated absolute counts of CD4+ (P = 0.002) and CD8+ (P < 0.001) T cells as well as CD4+ and CD8+ cells bearing HLA-DR (P < 0.01). The long-term administration of ibrutinib was associated with the increased numbers of CD4+ bearing HLA-DR (P = 0.006) and elevation of HLA-DR expression on all monocyte subsets (P ≤ 0.004). Our results provide the first evidence of the time-dependent immunomodulatory effect of ibrutinib on CLL and T cells and monocytes. The clinical consequences of time-dependent changes in HLA-DR expression in ibrutinib treated patients deserve further investigation.
650    _2
$a senioři $7 D000368
650    _2
$a CD4-pozitivní T-lymfocyty $x metabolismus $x patologie $7 D015496
650    _2
$a CD8-pozitivní T-lymfocyty $x metabolismus $x patologie $7 D018414
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a regulace genové exprese u leukemie $x účinky léků $7 D015973
650    _2
$a HLA-DR antigeny $x biosyntéza $7 D006684
650    _2
$a lidé $7 D006801
650    12
$a chronická lymfatická leukemie $x farmakoterapie $x metabolismus $x patologie $7 D015451
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a nádorové proteiny $x biosyntéza $7 D009363
650    _2
$a pyrazoly $x aplikace a dávkování $7 D011720
650    _2
$a pyrimidiny $x aplikace a dávkování $7 D011743
650    _2
$a časové faktory $7 D013997
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Turcsanyi, Peter $u Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic.
700    1_
$a Mikulkova, Zuzana $u Department of Immunology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic.
700    1_
$a Gabcova, Gabriela $u Department of Immunology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic.
700    1_
$a Urbanova, Renata $u Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic.
700    1_
$a Gajdos, Petr $u Department of Computer Science, Faculty of Electrical Engineering and Computer Science, VSB-Technical University of Ostrava, Czech Republic.
700    1_
$a Smotkova Kraiczova, Veronika $u Department of Immunology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic.
700    1_
$a Zehnalova, Sarka $u Department of Computer Science, Faculty of Electrical Engineering and Computer Science, VSB-Technical University of Ostrava, Czech Republic.
700    1_
$a Papajik, Tomas $u Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic.
700    1_
$a Kriegova, Eva $u Department of Immunology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic. Electronic address: eva.kriegova@email.cz.
773    0_
$w MED00003141 $t Leukemia research $x 1873-5835 $g Roč. 72, č. - (2018), s. 113-119
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30149317 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190813 $b ABA008
991    __
$a 20190819115342 $b ABA008
999    __
$a ok $b bmc $g 1433399 $s 1066710
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 72 $c - $d 113-119 $e 20180810 $i 1873-5835 $m Leukemia research $n Leuk Res $x MED00003141
GRA    __
$a NV16-32339A $p MZ0
LZP    __
$a Pubmed-20190813

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace

Nahrávání dat ...